Abstracts tagged "juvenile idiopathic arthritis (JIA) and pediatric rheumatology"

Abstract Number: 2390 • 2018 ACR/ARHP Annual Meeting
Incidence of and Risk Factors for Adrenal Suppression Following Ultrasound-Guided Intra-Articular Corticosteroid Injection with Triamcinolone Acetonide in Juvenile Idiopathic Arthritis
Katherine K Ngo¹, Angelina Bernier¹, Melissa E Elder², Renee F Modica² and Akaluck Thatayatikom¹, ¹Pediatrics, University of Florida, Gainesville, FL, ²Department of Pediatrics, University of Florida, Gainesville, FL
Background/Purpose: Intra-articular corticosteroid injection (IACI) is routinely used in juvenile idiopathic arthritis (JIA) with oligoarticular disease and as adjunct therapy for other types of JIA.…
Abstract Number: 2397 • 2018 ACR/ARHP Annual Meeting
The Impact of Adalimumab on Growth in Patients with Pediatric Enthesitis-Related Arthritis
Rubén Burgos-Vargas¹, Shirley M.L. Tse², Kirsten Minden³, Pierre Quartier⁴, Jaclyn K. Anderson⁵, Kristina Unnebrink⁶, Ivan Lagunes Galindo⁵ and Gerd Horneff⁷, ¹Hospital General de Mexico, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Charite University Medicine, Berlin, Germany, ⁴Hopital Necker-Enfants Malades, Paris, France, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Deutschland GmbH & Co., Ludwigshafen, Germany, ⁷Asklepios Clinic Sankt Augustin, and University Hospital of Cologne, Cologne, Germany
Background/Purpose: Children with one or more subtypes of juvenile idiopathic arthritis, such as enthesitis-related arthritis (ERA), often exhibit growth impairments. The purpose of the analysis…
Abstract Number: 2032 • 2018 ACR/ARHP Annual Meeting
Effector T Helper Cell Differentiation and Cytokine Secretion Are Increased in Young Children with Juvenile Idiopathic Arthritis
Anna Patrick¹, Thomas Aune², Jessica Duis³ and T. Brent Graham⁴, ¹Pediatric Rheumatology, Monroe Carell Junior Children's Hospital at Vanderbilt, Division of Pediatric Rheumatology, Nashville, TN, ²Medicine, Vanderbilt University Medical Center, Division of Rheumatology, Nashville, TN, ³Pediatrics, Monroe Carell Junior Children's Hospital at Vanderbilt, Division of Medical Genetics and Genomic Medicine, Nashville, TN, ⁴Pediatrics, Monroe Carell Junior Children's Hospital at Vanderbilt, Division of Pediatric Rheumatology, Nashville, TN
Background/Purpose: T cells play a critical role in the body’s response to pathogens. A naïve T helper (Th0) cell proliferates in response to antigen encounter…
Abstract Number: 9 • 2017 Pediatric Rheumatology Symposium
Biologically-Based Approach for Classifying Chronic Childhood Arthritis
Elham Rezaei¹, Daniel Hogan², Brett Trost², Anthony Kusalik², Susanne Benseler³, Gilles Boire⁴, David A. Cabral⁵, Bonnie Cameron⁶, Sarah Campillo⁷, Gaëlle Chédeville⁸, Paul Dancey⁹, Ciarán M. Duffy¹⁰, Karen N Watanabe Duffy¹¹, Janet Ellsworth¹², Simon Eng¹³, Brian M. Feldman¹⁴, John Gordon², Jaime Guzman¹⁵, Kristin Houghton¹⁶, Adam Huber¹⁷, Quaid Morris¹³, Bianca Lang¹⁸, Deborah M. Levy¹⁹, Loren Matheson²⁰, Kiem Oen²¹, Ross Petty²², Suzanne Ramsey²³, Johannes Roth²⁴, Dax Rumsey²⁵, Claire Saint-Cyr²⁶, Rayfel Schneider²⁷, Rosie Scuccimarri²⁸, Earl Silverman¹⁹, Lynn R. Spiegel²⁹, Elizabeth Stringer¹⁸, Shirley M.L. Tse³⁰, Lori Tucker³¹, Rae S.M. Yeung³² and Alan Rosenberg¹, ¹Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ²University of Saskatchewan, Saskatoon, SK, Canada, ³Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ⁴Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, ⁵Pediatrics/Rm K4-121, BC Children's Hospital, Vancouver, BC, Canada, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷Montreal Children's Hospital, Montreal, QC, Canada, ⁸Rheumatology, McGill University, Montreal, QC, Canada, ⁹Pediatrics, Janeway Children's Hospital, St. John's, NL, Canada, ¹⁰Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ¹¹Rheumatology, Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ¹²University of Alberta, Edmonton, AB, Canada, ¹³University of Toronto, Toronto, ON, Canada, ¹⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁵Rheumatology, BC Children's Hospital, Vancouver, BC, Canada, ¹⁶Rheumatology/Pediatrics, British Columbia Childrens Hos, Vancouver, BC, Canada, ¹⁷IWK Health Centre, Halifax, NS, Canada, ¹⁸Dalhousie University, Halifax, NS, Canada, ¹⁹Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²⁰University of Saskatchewan, Ottawa, ON, Canada, ²¹University of Manitoba, Winnipeg, MB, Canada, ²²Pediatric Rheumatology, Division of Rheumatology, BC Children's Hospital, Vancouver, BC, Canada, ²³Pediatric Rheumatology, IWK Health Centre, Halifax, NS, Canada, ²⁴Pediatric Rheumatology, Children's Hospital Eastern On, Ottawa, ON, Canada, ²⁵Stollery Children's Hospital, Edmonton, AB, Canada, ²⁶Pediatrics, CHU Sainte-Justine, Montreal, QC, Canada, ²⁷Division of Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ²⁸Division of Pediatric Rheumatology, Montreal Children's Hospital/McGill University Health Centre, Montreal, QC, Canada, ²⁹Rheumatology/Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada, ³⁰Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ³¹Pediatric Rheum/Rm K4-120, BC Childrens Hospital, Vancouver, BC, Canada, ³²Paediatrics, Immunology and Medical Science, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) comprises a heterogeneous group of conditions that share chronic arthritis as a common characteristic. International uniformity in classifying JIA, based…
Abstract Number: 116 • 2017 Pediatric Rheumatology Symposium
Arthritis as First Presenting Symptom of Inflammatory Bowel Disease: A Case Control Study
Kathryn Phillippi¹, Thomas Sferra², Nora Singer³ and Elizabeth Brooks⁴, ¹Pediatric Infectious Diseases and Rheumatology, Rainbow Babies and Children’s Hospital / Case Medical Center, Cleveland, OH, ²Pediatric Gastroenterology, Rainbow Babies and Children's Hospital/Case Medical Center, Cleveland, OH, ³MetroHealth Medical Center and Case Western Reserve University, Cleveland, Ohio, Cleveland, OH, ⁴Division of Pediatric Infectious Diseases and Rheumatology, Rainbow Babies and Children’s Hospital / Case Medical Center, Cleveland, OH, Cleveland, OH
Background/Purpose: Inflammatory bowel disease (IBD) is associated with extra-intestinal manifestations, the most common of which is arthralgia/arthritis. 4.1- 15% of patients with inflammatory bowel disease…
Abstract Number: 393 • 2016 ACR/ARHP Annual Meeting
Association of Sex, Race and Ethnicity on Disease Outcomes in Juvenile Idiopathic Arthritis Patients
Vivek Joseph¹, Tracy R. Andrews², Esi Morgan³, Ronald Laxer⁴, cagri Toruner⁵, Tzielan Lee^6,7, Beth S. Gottlieb⁸, C. April Bingham⁹, Sheetal S. Vora¹⁰, Jon M. Burnham¹¹, Judyann C. Olson¹², Murray H. Passo¹³, Michelle Batthish¹⁴, Meredith Riebschleger¹⁵ and Jennifer E. Weiss¹⁶, ¹Internal Medicine, Rutgers New Jersey Medical School, Bloomfield, NJ, ²Biostatistics, David & Alice Jurist Institute, Hackensack University Medical Center, hackensack, NJ, ³Pediatric Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH, ⁴Div of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Rheumatology, Nationwide Children's Hospital, Columbus, OH, ⁶Dept of Pediatric Rheumatology, Stanford Univ School of Med, Palo Alto, CA, ⁷Pediatric Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ⁸Pediatric Rheumatology, The Steven and Alexandra Cohen Children's Medical Center of New York, The Hofstra North Shore-LIJ School of Medicine, New Hyde Park, NY, ⁹Penn State Health Children's Hospital, Hershey, PA, ¹⁰Pediatric Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ¹¹Pediatric Rheumatology, Children's Hospital Philadelphia, Philadelphia, PA, ¹²Ped/MACC Fund Research Ctr, Medical College of Wisconsin, Milwaukee, WI, ¹³Division of Rheumatology PTD, Medical University of South Carolina, Charleston, SC, ¹⁴Division of Pediatric Rheumatology, McMaster Children's Hospital, Hamilton, ON, Canada, ¹⁵Pediatric Rheumatology, University of Michigan, CS Mott Children's Hospiatl, Ann Arbor, MI, ¹⁶Hackensack Univ Med Ctr, Hackensack, NJ
Background/Purpose: JIA patients are predominantly non-Hispanic white and studies have shown that race and ethnicity may be associated with worse disease. This study assesses the…
Abstract Number: 1355 • 2016 ACR/ARHP Annual Meeting
ASAH1 Gene Mutations Cause Acid Ceramidase Deficiency (Farber Disease), with Symptoms Including Arthritis and Subcutaneous Nodules. Patients Are Often Misdiagnosed with JIA, and Slowly Progressive Disease May Only be Diagnosed in Adulthood
Alexander Solyom¹, Calogera Simonaro² and Edward Schuchman³, ¹Roivant Sciences, New York, NY, ²Genetics & Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, ³Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Mutations in the ASAH1 gene cause acid ceramidase deficiency, accumulation of the pro-inflammatory and pro-apoptotic lipid ceramide, and a distinct set of clinical features,…
Abstract Number: 933 • 2014 ACR/ARHP Annual Meeting
A Multi-Center, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab in Pediatric Patients with Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy: Week 48 Results
Hermine I. Brunner¹, Nicolino Ruperto², N Tzaribachev³, Gerd Horneff⁴, Carine Wouters⁵, Violeta Vladislava Panaviene⁶, Vyacheslav Chasnyk⁷, Carlos Abud-Mendoza⁸, Ruben Cuttica⁹, Andreas Reiff¹⁰, M Maldonado-Velázquez¹, Nadina Rubio-Pérez¹¹, Rik Joos¹², V Keltsev¹³, Evgeny Nasonov¹⁴, Daniel Kingsbury¹⁵, M Bandeira¹⁶, Earl Silverman¹⁷, F Weller-Heinemann¹¹, A van Royen-Kerkhof¹⁸, Alan M. Mendelsohn¹⁹, Lilianne Kim²⁰, Daniel Lovell²¹ and A Martini²², ¹PRCSG, Cincinnati, OH, ²Pediatria II,, Istituto Giannina Gaslini, Genoa, Italy, ³PRINTO & PRCSG, Bramstedt, Germany, ⁴Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁵Pediatric Rheumatology, University Hosp Gasthuisberg, Leuven, Belgium, ⁶Istituto Giannina Gaslini, Genoa, Italy, ⁷Litovskaya Str., 2, Novartis Pharma, Saint-Peterburg, Russia, ⁸Unidad de Investigaciones Reumatológicas, Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ⁹Tilcara 3023, Hospital de Ninos Pedro de Elizalde, Capital Federal, Argentina, ¹⁰Children’s Hospital of Los Angeles, Los Angeles, CA, ¹¹PRINTO, Genoa, Italy, ¹²UZ Gent, Gent, Belgium, ¹³Paediatric Rheumatology International Trials Organisation–IRCCS [PRINTO], Genoa, Italy, ¹⁴State Institute of Rheumatology of RAMS, Moscow, Russia, ¹⁵Pediatric Rheumatology, Randall Children's Hospital at Legacy Emanuel, Portland, OR, ¹⁶Pediatrics, Hospital Infantil Pequeno Príncipe, Curitiba, Brazil, ¹⁷Division of Rheumatology, Hosp for Sick Children, Toronto, ON, Canada, ¹⁸Department of Pediatric Immunology & Rheumatology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, Netherlands, ¹⁹Immunology, Janssen Research & Development, LLC., Spring House, PA, ²⁰Janssen Research & Development, LLC., Spring House, PA, ²¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, OH, ²²Istituto Gaslini-PRINTO, Genova, Italy
Background/Purpose: To assess efficacy and safety of SC golimumab (GLM) in polyarticular pediatric juvenile idiopathic arthritis pts (aged 2 to
Abstract Number: 281 • 2014 ACR/ARHP Annual Meeting
Retrospective Review of Immobilization Vs. Immediate Resumption of Activity in Patients with Oligoarticular Juvenile Idiopathic Arthritis and Corticosteroid Knee Injections
Elaine Ramsay¹, Heather Benham², Jenna Tress³, Janille Diaz⁴ and David D. Sherry³, ¹Pediatric Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ²Pediatric Rheumatology, Texas Scottish Rite Hospital for Children, Dallas, TX, ³Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Pediatric Rheumatology, The Children's Hospital of Philadelphia, Philadelphia,, PA
Background/Purpose Intraarticular corticosteroid injection (IACI) is one of the most common treatment modalities in oligoarticular Juvenile Idiopathic Arthritis (JIA). There is widespread use of IACI…
Abstract Number: 292 • 2014 ACR/ARHP Annual Meeting
Flares in Children with JIA: Results from the Reacch-out Cohort
Lori B. Tucker¹, Jaime Guzman¹, Kiem Oen² and ReACCh Out Investigators³, ¹Rheumatology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ²Pediatrics, Children's Hospital of Winnipeg and University of Manitoba, Winnipeg, MB, Canada, ³BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: Disease flares are a concern to patients with JIA, their parents, and caregivers alike; but little is known of disease manifestations during a…
Abstract Number: 270 • 2014 ACR/ARHP Annual Meeting
Disease Burden Is Comparable in Children with Enthesitis-Related Arthritis and Polyarticular Juvenile Idiopathic Arthritis
Pierre Quartier¹, Jasmina Kalabic², Zbigniew Zuber³, Kirsten Minden⁴ and Jaclyn K. Anderson⁵, ¹Pediatric Rheumatology, IMAGINE Institute, Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Université Paris-Descartes, Paris, France, ²AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ³St. Louis Children’s Hospital, Krakow, Poland, ⁴Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: To compare baseline disease characteristics of pediatric patients (pts) with enthesitis-related arthritis (ERA) and polyarticular juvenile idiopathic arthritis (pJIA) from clinical trials with adalimumab…
Abstract Number: 2865 • 2013 ACR/ARHP Annual Meeting
Gene Expression Profiles Of Fibroblast-Like Synoviocytes In Early Stage Of Oligoarticular Juvenile Idiopathic Arthritis Are Different In Extended Versus Persistent Course
AnneMarie C. Brescia¹, Megan M. Simonds², Suzanne M. McCahan², Paul T. Fawcett² and Carlos D. Rose¹, ¹Pediatric Rheumatology, Thomas Jefferson University/ AI duPont Hospital for Children, Wilmington, DE, ²Nemours Research, Nemours/AI duPont Hospital for Children, Wilmington, DE
Background/Purpose: Our goal is the identification of informative synovial biomarkers to predict persistent vs extended course in oligoarticular JIA patients. Methods: Stored remnant synovial fluid…
Abstract Number: 1150 • 2012 ACR/ARHP Annual Meeting
Adverse Events in Juvenile Idiopathic Arthritis: Results From the Enhanced Drug Safety Surveillance (EDSS) Pilot Project
Sarah Ringold¹, Audrey F. Hendrickson², Carol A. Wallace³ and Rachel E. Sobel⁴, ¹Pediatrics, Seattle Children's Hospital/Univ of Washington, Seattle, WA, ²Rheumatology, Seattle Children's Research Institute, Seattle, WA, ³Pediatrics, Seattle Childrens Hospital, Seattle, WA, ⁴Epidemiology, Worldwide Safety Strategy, Pfizer, Inc., New York, NY
Background/Purpose: There are few data available regarding the rates of serious and important medical events (SAEs and IMEs) for most of the medications used to…
Abstract Number: 862 • 2012 ACR/ARHP Annual Meeting
What Is the Impact of a Transition Program On Adolescents with Juvenile Idiopathic Arthritis and Their Parents ?
Deborah Hilderson¹, Rene Westhovens², Rik Joos³, Carine H. Wouters⁴ and Philip Moons⁵, ¹Department of Paediatrics; Centre for Health Services and Nursing Research, University Hospital Leuven, KU Leuven, Leuven, Belgium, ²Rheumatology Department of development and regeneration, University Hospital KU Leuven, Leuven, Belgium, ³PRINTO, Genoa, Italy, ⁴Pediatric Rheumatology, University Hospital KU Leuven, Leuven, Belgium, ⁵Centre for Health Services and Nursing Research, KU Leuven, Leuven, Belgium
Background/Purpose: To date, there is no structured or systematic approach in Belgium for transferring adolescents with juvenile idiopathic arthritis from pediatric rheumatology to an adult…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].